Literature DB >> 2581988

Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue.

J Liu, J Geller, J Albert, M Kirshner.   

Abstract

To examine the relationship between whole prostatic dihydrotestosterone (DHT) concentrations and epithelial and stromal protein synthesis, patients awaiting surgery for benign prostatic hypertrophy were given medication to reduce circulating and tissue androgen levels for comparison to levels in untreated patients. The medications, either megestrol acetate, a progestational antiandrogen, or megestrol acetate plus dexamethasone, were given for 1 week before surgery. Aliquots of prostate tissue obtained at surgery were assayed for DHT. The remainder of the tissue was separated into stromal and epithelial cells using enzymatic separation; the incorporation of both [3H] proline into stromal protein and [3H]leucine into epithelial cell protein was then measured. Over a wide range of tissue DHT concentrations, DHT correlated significantly with [3H]proline incorporation into stromal protein (r = 0.58). Likewise, epithelial cell incorporation of [3H]leucine into protein correlated significantly with tissue DHT concentrations, with a r value of 0.79. In the case of stromal cells, no additional effects of dexamethasone given with megestrol acetate were found on stromal protein synthesis. Epithelial cell [3H]leucine incorporation into protein was paradoxically enhanced by dexamethasone plus megestrol acetate compared to the latter alone, despite the fact that tissue DHT and circulating adrenal androgens, dehydroepiandrosterone sulfate and delta 4-androstenedione, were not significantly different from values obtained after treatment with megestrol acetate alone. These studies support the conclusion that there is a dominant role of DHT in regulating protein synthesis in both prostatic epithelial and stromal cells. Dexamethasone appears to have a growth-stimulating effect on prostatic epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2581988     DOI: 10.1210/jcem-61-1-129

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate.

Authors:  Seetha Venkateswaran; David Margel; Stanley Yap; Karen Hersey; Paul Yip; Neil Eric Fleshner
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

Review 2.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

Review 3.  Targeting treatment options for castration-resistant prostate cancer.

Authors:  Dannah R Miller; Matthew A Ingersoll; Benjamin A Teply; Ming-Fong Lin
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

4.  Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).

Authors:  J Geller; J Albert
Journal:  Urol Res       Date:  1987

Review 5.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.

Authors:  Elahe A Mostaghel; Peter S Nelson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

Review 6.  Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.

Authors:  Elahe A Mostaghel; Bruce Montgomery; Peter S Nelson
Journal:  Urol Oncol       Date:  2009 May-Jun       Impact factor: 3.498

7.  Steroid hormone synthetic pathways in prostate cancer.

Authors:  Elahe A Mostaghel
Journal:  Transl Androl Urol       Date:  2013-09

8.  Genomic and epigenomic alterations in prostate cancer.

Authors:  Anna M Aschelter; Silvana Giacinti; Paola Caporello; Paolo Marchetti
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-06       Impact factor: 5.555

Review 9.  Development and prevalence of castration-resistant prostate cancer subtypes.

Authors:  Jordan E Vellky; William A Ricke
Journal:  Neoplasia       Date:  2020-09-25       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.